PDUFA public meeting
This article was originally published in The Tan Sheet
Executive SummaryFDA will host a public meeting to gather stakeholder feedback on the Prescription Drug User Fee Act (PDUFA) Nov. 14 from 9 a.m. to 5 p.m. The agency requests that the public consider two questions in preparation for the meeting or submitted comments: "What is your assessment of the overall performance of the PDUFA programs thus far?" and "What aspects of PDUFA should be retained, or what should be changed to further strengthen and improve the program?" Current PDUFA legislation will expire in September 2007. Those planning to attend the meeting must be registered by Oct. 31 and written comments must be submitted by Dec. 14, FDA states...
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.